Tetraphase Pharmaceuticals continues to reel from the spectacular and unexpected failure of its flagship candidate, eravacycline.
When investors see a drop of almost 80% in a share price, the question of long-term viability is almost impossible to ignore.
Wednesday’s top analyst upgrades, downgrades and initiations include Celgene, Ciena, Goldman Sachs, MannKind, Newfield Exploration, Tetraphase Pharmaceuticals, Walgreens Boots Alliance and Yingli...
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of September and added some color.
SunTrust Robinson Humphrey handicaps some of the upcoming events for stocks in the firm's coverage universe that have potential market-moving clinical and FDA catalysts during the remainder of 2015.
In a new report, the analysts at Stifel are very positive on two companies leading the charge against antibiotic-resistant "super bugs."
Whether the market wants to sell off or wants to again go back and challenge all-time highs, a slew of companies have filed to raise billions of dollars worth of capital.
A new research piece from Cantor Fitzgerald highlights the stocks expected to see the biggest number of shares changing hands on Friday's Russell 2000 rebalancing.
Source: ThinkstockEarnings season has wound down for the most part, and Tuesday’s market reaction saw a drop of just over 1 point on the S&P 500 (closed at 2,002.28) and the Dow closed down almost...
Source: ThinkstockOne of the main concerns physicians have agreed upon in recent years has been the overuse of antibiotics by some health care professionals. Their overuse in some cases has led many...